Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes
- 1 June 2016
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 44 (6) , 867-870
Abstract
Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-drug interactions (DDIs) with metabolic and transport proteins in sandwich-cultured human hepatocytes (SCHH). Tolvaptan was incubated with SCHH and quantified by liquid chromatography–tandem mass spectrometry. Pioglitazone, verapamil, MK-571, and elacridar were used as inhibitors to investigate mechanisms of transport and metabolism of tolvaptan and metabolites. Taurocholate (TCA), pravastatin, digoxin, and metformin were used as transporter probes to investigate which transport proteins were inhibited by tolvaptan and metabolites. Cellular accumulation of tolvaptan (0.15–50 μM), DM-4103, and DM-4107 in SCHH was concentration-dependent. Tolvaptan accumulation (15 μM) in SCHH was not altered markedly by 50 μM pioglitazone, verapamil, MK-571, or 10 μM elacridar. Coincubation of tolvaptan with pioglitazone, verapamil, MK-571, and elacridar reduced DM-4107 accumulation by 45.6, 79.8, 94.5, and 23.0%, respectively, relative to control. Coincubation with increasing tolvaptan concentrations (0.15–50 μM) decreased TCA (2.5 μM) cell+bile accumulation and the TCA biliary excretion index (BEI; from 76% to 51%), consistent with inhibition of the bile salt export pump (BSEP). Tolvaptan (15 μM) had no effect on the cellular accumulation of 2.5 μM pravastatin or metformin. Digoxin cellular accumulation increased, and the BEI of digoxin decreased from 23.9 to 8.1% in the presence of 15 μM tolvaptan, consistent with inhibition of P-glycoprotein. In summary, SCHH studies revealed potential metabolic- and transporter-mediated DDIs involving tolvaptan and metabolites.Keywords
This publication has 17 references indexed in Scilit:
- Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug InteractionsJournal of Clinical Medicine, 2014
- Cytochrome P450 Inhibitory Properties of Common Efflux Transporter InhibitorsDrug Metabolism and Disposition, 2014
- Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjectsBritish Journal of Clinical Pharmacology, 2012
- Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2012
- Oral Tolvaptan Is Safe and Effective in Chronic HyponatremiaJournal of the American Society of Nephrology, 2010
- Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug DevelopmentThe AAPS Journal, 2009
- Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single‐Dose Studies in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007
- Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and InhibitionDrug Metabolism and Disposition, 2003
- Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P 4503A4AAPS PharmSci, 1999
- Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configurationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1999